奥沙利铂联合卡培他滨治疗进展期胃癌47例的临床观察  

作　　者：陈伙辉 陈燕武[1] 吴凤坚 陈广幸[1] 

机构地区：[1]广东省肇庆市第二人民医院肿瘤科,广东肇庆526020

出　　处：《中外医疗》2009年第11期6-7,共2页China & Foreign Medical Treatment

摘　　要：目的评价奥沙利铂联合卡培他滨方案治疗进展期胃癌的临床疗效和安全性。方法用奥沙利铂联合卡培他滨方案治疗进展期胃癌患者47例。方案为奥沙利铂(OXA)200mg/m2,静脉滴注2h,第1天。卡培他滨2000mg/m2,口服,2次/d,第1～14天,服用2周后休息1周。每3周重复1次,行6周期(18周)治疗后判定疗效。结果完全有效(CR)4例(8.51%),部分有效(PR)17例(36.17%),稳定(SD)20例(42.56%),进展(PD)6例(12.77%)。总有效率(ORR)44.68%(21/47),中位肿瘤进展时间分别为6.97个月,1年生存率分别为50.5%。主要不良反应为恶心、呕吐和中性粒细胞减少,未出现治疗相关性死亡。结论奥沙利铂联合卡培他滨治疗进展期胃癌患者临床疗效较高,不良反应轻而且安全。Objective To evaluate the effects and safety of Oxaliplatin in combination with capecitabine for patients in the treatment of advanced gastric cancer. Methods Forty-seven patients with advanced gastric cancer were treated by Oxaliplatin in combination with capecitabine. The Oxaliplatin 209mg/m^2 iv 2hr,article 1day, and capecitabine 2000mg/m^2,po,bid,article 1--14 days,and repeated every 3 weeks（one cycle）. The effect was evaluated after six cycles（18 weeks）. Results Four patients achieved CR（8.51%）, 17 PR（36.17%）, 20 SD（42.56%） and 6 PD（12.77%）. Overall response rate（ORR） for chemotherapy patients were 44.68.0%（21/47）, median TTP was 6.97 months,one year survival rate was 50.5%.The main adverse reaction were nausea, vomit and neutrocytopenia. There were no any deaths during treament.Conclusion Oxaliplatin in combination with capecitabine is an effective and well tolerated in patients with advanced gastric cancer.

关 键 词：胃癌 化疗 奥沙利铂 卡培他滨 

分 类 号：R735[医药卫生—肿瘤]